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Abstract
Background: Lithium augmentation of antidepressants is an effective strategy in treatment-resistant depression. The 
proteohormone ghrelin is thought to be involved in the pathophysiology of depression. The purpose of this study was to 
investigate the association of treatment response with the course of ghrelin levels during lithium augmentation.
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Method: Ghrelin serum concentrations and severity of depression were measured in 85 acute depressive patients before and 
after 4 weeks of lithium augmentation.
Results: In a linear mixed model analysis, we found a significant effect of response*time interaction (F1.81 = 9.48; P = .0028): 
under treatment, ghrelin levels increased in nonresponders and slightly decreased in responders to lithium augmentation. 
The covariate female gender had a significant positive effect (F1.83 = 4.69; P = .033), whereas time, response, appetite, and body 
mass index (kg/m2) did not show any significant effect on ghrelin levels (P > .05).
Conclusion: This is the first study showing that the course of ghrelin levels separates responders and nonresponders to 
lithium augmentation. Present results support the hypothesis that ghrelin serum concentrations might be involved in 
response to pharmacological treatment of depression.
Keywords: ghrelin, lithium augmentation, response, depression, therapy resistant depression.
Introduction
The role of the proteohormone ghrelin in the pathophysiology of 
depression is currently discussed. While ghrelin is secreted mainly 
at the fundus of the stomach, only small amounts are produced in 
the central nervous system. Ghrelin is able to cross the blood brain 
barrier and stimulates appetite and food intake by binding to its 
receptor (GHS-R1a) in the hypothalamus. GHS-R1a is expressed 
in numerous neuronal populations, and therefore the physio-
logical role of ghrelin might include learning, memory, anxiety, 
depression, and neuroprotection (Dos Santos et al., 2013). A recent 
observation showed that plasma acylated ghrelin is associated 
with neural abnormalities in the ventral tegmental area, thereby 
modulating the reward system, which has been implicated in the 
pathophysiology of depression. Ghrelin modulates monoamine 
neurotransmission and the HPA axis, which both play an import-
ant role in the pathophysiology of depression. Furthermore, a 
polymorphism on ghrelin’s encoding gene was described to be 
associated with depression (Nakashima et al., 2008). An increase 
in ghrelin levels occurs not only in states of anergia but also fol-
lows acute and chronic stress. In summary, ghrelin signalling 
could play an important role in the pathophysiology of major 
depressive disorder (MDD), which still needs to be clarified.
Meta-analytical data show lithium augmentation (LA) of anti-
depressants as an effective strategy in MDD. The mechanisms 
underlying therapeutic efficacy of LA are still poorly understood, 
and individual response to LA cannot yet be predicted (Bauer 
et al., 2014). To the best of our knowledge, the course of ghrelin 
serum levels during lithium treatment and the association of 
treatment response with the course of ghrelin serum levels in 
the treatment of depression have not yet been investigated.
The purpose of this study was to investigate the association 
of treatment response with the course of ghrelin levels during 
LA by measuring ghrelin before and during LA in patients with 
MDD in a prospective cohort study.
We hypothesized that ghrelin is influenced by LA and that 
there is a different effect of LA in responders and nonrespond-
ers on ghrelin levels.
Methods
The study population was a subsample of a prospective cohort 
study investigating treatment response and side effect burden 
of LA in MDD. In this subsample, data on serum levels of ghrelin 
(baseline and study endpoint) were available in 85 patients (71 in- 
and 14 outpatients). The inclusion criteria were: MDD (according 
to DSM-IV cirteria) (American Psychiatric Association, 1994), age 
older than 18 years, indication for an antidepressant pharma-
cotherapy, insufficient response to an adequate antidepressant 
pretreatment and clinical indication for lithium augmentation, 
a Hamilton Depression Rating Scale (HDRS-17; Hamilton 1960) 
score ≥12, and written informed consent. The respective diagno-
sis was confirmed using the Mini-International Neuropsychiatric 
Interview (Sheehan et al., 1998). Patients were recruited between 
December 2008 and December 2012 in 12 psychiatric depart-
ments of the Berlin Research Network on Depression. The local 
ethics committee approved the study, and written informed 
consent was obtained from all subjects.
Ghrelin serum concentrations (nonfasting) were first meas-
ured in medicated patients before LA (baseline) and then after 
4 weeks of co-medication with lithium (endpoint). Severity of 
depression (measured with HDRS-17) and body mass index (BMI, 
kg/m2) were measured on both occasions. Clinical response was 
defined as a HDRS-17 decrease of 50% or more. All patients 
received individual doses of lithium carbonate adapted to their 
individual lithium serum levels.
Endogenous ghrelin levels were measured in the rethawed 
serum samples using RayBio Ghrelin Enzyme Immunoassay 
(EIA) Kit, an in vitro quantitative assay based on the principle 
of competitive enzyme immunoassay. The detection range was 
0.1 to 1.000 ng/mL, the intra-assay CV was <10%, and the inter-
assay CV was <15%, according to the manufacturer’s specifica-
tions (RayBio Human Ghrelin EIA Kit Protocol, 2013).
We used a linear mixed model for statistical analysis to inves-
tigate the effect of LA (time) as an explanatory factor for change in 
ghrelin levels. The differential effect of response to LA on change 
in ghrelin levels is represented by a response*time interaction 
term. Linear mixed-effects models have the advantage of allowing 
the investigation of variability between patients (heterogeneity) 
and simultaneously adjusting for the within-subject correlation. 
In the present analysis, random effects were permitted for the 
intercepts. We entered time, gender, BMI, appetite, response, 
and response*time interaction as fixed effects into the model. To 
control for the effect of appetite on ghrelin levels, we used the 
HRDS-17 item “12. Somatic symptoms (gastrointestinal)”. Model 
regression coefficients are reported together with their 95% CI. 
We used SAS software, version 9.4. to perform the linear mixed 
model analysis and SPSS (version 21)  for descriptive statistics, 
paired sample t test, and repeated-measures ANOVA-rm (Table 1). 
Significance level was set at .05 in all analyses.
Results
Table  1 provides information on measured ghrelin levels and 
clinical data as well as a basic statistical analysis of group char-
acteristics (responders vs nonresponders) and the data that 
was used for linear mixed model analysis. In the following text 
and in Figure 1, we present estimated values of ghrelin levels 
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as a result of the linear mixed model analysis. These estimates 
describe the influence of the respective patient characteristics 
on ghrelin levels. The result of the linear mixed model analysis 
is the main result of the study. For n = 85 patients, 169 observa-
tions of ghrelin levels were used for linear mixed model analysis 
(a baseline measurement for 1 patient was missing). A signifi-
cant effect on ghrelin levels was found for response*time inter-
action (F1.81 = 9.48; P = .0028) and gender (F1.83 = 4.69; P = .033). In 
this model, BMI (F1.91 = 0.22; P = .64), response (F1.84 = 0.14; P = .71), 
appetite (F1.113 = 0.95; P = .33), and time (equal to “treatment 
effect of LA”; F1.83 = 1.58; P = .21) did not show a significant effect 
on ghrelin levels. The main finding of the study (significant 
response*time interaction) is demonstrated in Figure 1 by the 
crossed regression graphs. In this analysis, the estimated ghre-
lin levels do not differ significantly between responders and 
nonresponders at baseline and after LA (overlapping 95% CI). 
The estimated ghrelin levels at baseline were 4.51 ng/mL (95% 
CI: 2.61–6.41; P < .0001) in nonresponders and 6.45 ng/mL (95% 
CI: 4.30–8.61; P < .0001) in responders. The estimated ghrelin lev-
els at endpoint were 6.53 ng/mL (95% CI: 4.65–8.41; P < .0001) in 
nonresponders and 5.62 ng/mL (95% CI: 3.41–7.83; P < .0001) in 
responders (Figure 1.). The estimated ghrelin levels in men were 
3.01 ng/mL lower compared with women (95% CI: -5.77 to 0.25; 
P = .033).
Discussion
This is the first study investigating the course of ghrelin serum 
levels and the effect of treatment response on ghrelin lev-
els during LA in patients with MDD. We found that during LA, 
Table 1. Clinical Data and Results
n (%) Responder Nonresponder P Value*
Patients 85 (100)
Female 53 (62.4) 18 (52.9) 35 (68.6)
Male 32 (37.6) 16 (47.1) 16 (31.4) >.1
Response 34 (40.0)
Nonresponse 51 (60.0)
Psychotropic comedication
 Antidepressants
 SSRI 47 (55.3) 16 (47.1) 31 (60.8) >.1
 SNRI 21 (24.7) 12 (35.3) 9 (17.6) .65
 TCA 9 (10.6) 4 (11.8) 5 (9.8) >.1
 NDRI 4 (4.7) 0 (0.0) 4 (7.8) .94
 Valdoxan 1 (1.2) 0 (0.0) 1 (1.9) >.1
 NaSSA 12 (14.1) 5 (14.7) 7 (13.7) >.1
 MAO-I 2 (2.4) 1 (2.9) 1 (1.9) >.1
Atypical antipsychotics 22 (25.9) 9 (26.5) 13 (25.5) >.1
Antiepileptic drugs 8 (9.4) 2 (5.9) 6 (11.8) >.1
Benzodiazepines 19 (22.4) 10 (29.4) 9 (17.6) >.1
Low-potency antipsychotics 4 (4.7) 0 (0.0) 4 (7.8) .94
Mean (SD) Responder mean (SD) Nonresponder mean (SD) P Value**
Age 85 (100) 48.31 ± 15.27 50.00 ± 15.56 47.18 ± 15.12 >.1
Lithium serum level (mmol/L) last visit 77 (90.6) 0.713 ± 0.152 0.704 ± 0.146 0.719 ± 0.157 >.1
HRDS-17 score baseline 85 (100) 21.32 ± 5.03 19.73 ± 4.94 22.35 ± 4.85 >.1
HDRS-17 score last visit 85 (100) 12.84 ± 7.59 5.79 ± 2.95 17.53 ± 5.91 <.01
BMI baseline 84 (98.8) 25.54 ± 5.74 26.27 ± 6.26 26.64 ± 6.14 >.1
BMI last visit 85 (100) 26.00 ± 5.69 25.15 ± 5.44 25.58 ± 5.39 >.1
Ghrelin serum level (ng/mL) baseline 84 (98.8) 5.71 ± 6.20 6.50 ± 5.44 5.46 ± 4.90 >.1
Ghrelin serum level (ng/mL) last visit 85 (100) 6.42 ± 6.99 5.12 ± 6.71 7.05 ± 8.07 <.05
Before lithium 
augmentation
After lithium  
augmentation
P Value***
Ghrelin serum level (ng/mL) 84 (98.8) 5.71 ± 6.20 85 (100) 6.42 ± 6.99 <.05
Ghrelin serum level (ng/mL) responder 36 (42.9) 6.50 ± 5.44 36 (42.4) 5.46 ± 4.90 >.1
Ghrelin serum level (ng/mL) nonresponder 48 (57.1) 5.12 ± 6.71 49 (57.6) 7.05 ± 8.07 <.05
HRDS-17 score 85 (100) 21.32 ± 5.03 85 (100) 12.84 ± 7.59 <.05
BMI 84 (98.8) 25.54 ± 5.74 85 (100) 26.00 ± 5.69 <.05+
BMI responder 34 (40.4) 26.27 ± 6.26 34 (40.0) 26.64 ± 6.14 .052
BMI nonresponder 50 (59.5) 25.15 ± 5.44  51 (60.0) 25.58 ± 5.39 <.05
Abbreviations: BMI, body mass index; HDRS-17, Hamilton Depression Rating Scale; MAO-I, mono amine oxidase inhibitor (tranylcypromine); NaSSA, noradrenergic 
and specifically serotonergic antidepressant (mirtazapine); NDRI, norepinephrine and dopamine reuptake inhibitor (bupropione); reuptake inhibitor; SNRI, serotonin 
and norepinephrine reuptake inhibitor; SSRI, serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
*Result of Chi-square test; **results of independent t test; all parameters were normally distributed; ***results of paired sample t test; all parameters were normally 
distributed; the comparison of ghrelin and BMI before and after lithium augmentation (LA) was conducted with 84 patients, whereas mean and SD for the observa-
tion after LA are displayed for 85 patients in this table to present all data that were used for linear mixed model analysis.
+No significant effect of response on the course of BMI during LA was found in an ANOVA-rm (P > .05).
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ghrelin levels increase in nonresponders and slightly decrease 
in responders.
Our findings are in line with a study that found higher 
ghrelin serum levels in nonresponders with MDD to antide-
pressant treatment when compared with responders and nor-
mal controls (Ishitobi et  al., 2012). These findings strengthen 
evidence that ghrelin might separate subgroups of depressive 
patients that respond to pharmacological treatment of depres-
sion. As depression-related stress continues in nonresponders 
but not (or less severely) in responders, our results are in line 
with studies reporting a stress-dependent increase in ghrelin 
levels (Rouach et al., 2007) and higher ghrelin serum levels in 
depressed individuals compared with healthy controls (Gecici 
et al., 2005).
The observed gender effect in our study is in line with pre-
vious studies reporting higher ghrelin levels in females than 
males in both healthy subjects (Chan et al., 2004) and depressed 
patients (Kluge et al., 2009).
Our finding of an increase of ghrelin levels in nonresponders 
and a decrease in responders is in line with a preclinical study 
that reported an antidepressant-like effect following inhibition 
of ghrelin secretion after central or peripheral injection of ghre-
lin antisense DNA in rats (Kanehisa et  al., 2006), suggesting a 
depressiogenic effect of ghrelin. A depressiogenic effect of ghre-
lin might theoretically be explained by the suppressive effect 
of ghrelin on serotonin release as well as its stimulatory action 
on HPA axis (Kluge et al., 2007). On the other hand, the majority 
of data, in particular from animal studies, revealed contrasting 
results (reviewed in Spencer et al., 2015; Wittekind and Kluge, 
2015) and reported antidepressive and anxiolytic effects of 
ghrelin infusion (Lutter et al., 2008; Carlini et al., 2012), which 
might theoretically be explained by a stimulating effect of ghre-
lin on norepinephrine neurotransmission (Date et al., 2006) or 
via inhibition of glycogen-synthase-kinase 3 beta (Zhang et al., 
2013). In this context, the ghrelin upregulation in nonresponders 
observed in our study could also be interpreted as an intrinsic 
or pharmacologically induced attempt to counteract depressive 
symptomatology. However, in a small sample, ghrelin infusion 
in patients with depression did not have a significant effect on 
depressive symptoms (Kluge et al., 2011). It is important to note 
that studies on the effect of ghrelin application have investigated 
short-term effects (15 minutes until a few days) after short-term 
application, whereas our study investigated long-term effects (4 
weeks) after long-term application; thus, comparability of study 
results is limited.
Another explanation for the increase of ghrelin levels in 
nonresponders and the decrease in responders could be that 
we “only” observe secondary effects of depressive symptoma-
tology and successful antidepressant treatment with LA: one of 
the main symptoms of MDD is reduced appetite and consecu-
tively reduced food intake. Starvation is known to be a strong 
cue for ghrelin release, which could contribute to the observed 
ghrelin increase in nonresponders. Responders start to eat nor-
mally because of the relief of depressive symptomatology, which 
consecutively results in a decrease of ghrelin levels. Noteworthy, 
the result of our analysis is corrected for the effect of appetite 
on ghrelin levels, and we did not find a significant effect of 
response on BMI, which therefore does not support this hypoth-
esis. Furthermore, other studies rather report lower (Barim et al., 
2009) or unchanged (Kluge et al., 2009) ghrelin serum levels in 
depressed subjects compared with healthy controls.
However, in our study, we did not find a correlation between 
severity of depression and ghrelin serum levels (data not shown). 
In summary, the course of ghrelin levels observed in our study 
could be interpreted in the context of either an antidepressive 
or a depressiogenic effect of ghrelin or rather reflect a secondary 
effect of depressive symptomatology, that is, reduced appetite 
and food intake.
Lithium has well-known neuroprotective effects (Bauer et al., 
2014) and acts as a glycogen-synthase-kinase 3 beta inhibi-
tor (Jope and Bijur, 2002). Interestingly, preclinical studies sug-
gest that ghrelin can function as a neuroprotective agent that 
inhibits apoptotic pathways (Zhang, 2013) and that inactivation 
of GSK-3B contributes to the antiapoptotic effects of ghrelin. 
In the current analysis, we found ghrelin influenced by LA. In 
previously published analyses, we found that serum levels of 
brain-derived neurotrophic factor (Ricken et al., 2013) and fibro-
blast growth factor 23 (Fakhri et al., 2014), both discussed in the 
Figure 1. Course of ghrelin levels in responders and nonresponders adjusted for gender and BMI: ghrelin increases in nonresponders and decreases slightly in respond-
ers to lithium augmentation. Ghrelin serum levels are presented as estimated means in ng/mL.
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context of neuroprotection, increased during LA. Therefore, one 
might speculate that ghrelin, brain-derived neurotrophic fac-
tor, and fibroblast growth factor 23 signalling are potentially 
involved in the neuroprotective action of lithium.
Previous studies investigating ghrelin levels during antide-
pressant treatment found an increase of serum ghrelin levels 
during treatment with maprotiline (Pinar et al., 2008) and ami-
triptyline (Huang et al., 2013), while a decrease in ghrelin serum 
levels was reported during treatment with citalopram (Barim 
et al., 2009) and mirtazapine (Schmid et al., 2006), electroconvul-
sive therapy (Kurt et al., 2007), or various antidepressive treat-
ment strategies (Nakashima et al., 2014). These heterogeneous 
findings could be due to different treatment strategies, small 
sample sizes, and different response rates. Limitations of these 
previous studies are small sample sizes and that ghrelin levels 
were not available together with longitudinally assessed clinical 
response data. The main strengths of our study are the relatively 
large sample size and the prospective study design. Our study 
extends existing data by providing (1) the first investigation of 
ghrelin serum levels during lithium treatment and (2) the first 
longitudinal investigation of the effect of treatment response on 
the course of ghrelin levels in patients with MDD.
Limitations of our study include the lack of a control group 
and a heterogeneous psychopharamcological comedication. We 
therefore cannot say if the observed changes in ghrelin levels 
are a lithium-specific effect. However, psychopharmacological 
comedication was stable during and before LA, and we did not 
find significant differences in this medication between respond-
ers and nonresponders, so that the influence of this confound-
ing variable is limited. Also, we measured nonfasting ghrelin 
levels that were not taken after a standard meal and we did not 
obtain information on the time of the day when the blood sam-
ples were taken. Ghrelin levels strongly depend on food intake, 
appetite, and the anticipation of food, and its secretion has a cir-
cadian rhythm (Kirsz and Zieba, 2011) that increases variation of 
ghrelin levels. Nevertheless, we think that the large sample size 
could sufficiently compensate this confounder. Furthermore, 
we only have a pre- and postmeasurement of ghrelin levels, so 
we cannot distinguish between cause and effect (i.e., do ghrelin 
levels influence treatment response or does treatment response 
influence ghrelin levels?). To investigate this, a series of ghrelin 
and psychometric measurements with shorter time intervals is 
recommended for future studies.
In conclusion, the present results support the hypothesis 
that ghrelin serum concentrations might be involved in the 
response to pharmacological treatment of depression. Based 
on our data, one might speculate that an increase of the ghre-
lin serum concentration might be an indicator of nonresponse 
to LA in patients suffering from treatment-resistant depres-
sion. Further studies are needed to separate specific effects of 
different antidepressants on ghrelin concentration but also to 
address ghrelin downstream mechanisms.
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